NCT04819737 Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences
| NCT ID | NCT04819737 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Multiple Sclerosis (MS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-07-18 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2022-07-18 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of multiple sclerosis according to established international criteria * Steroid free period: \> 4 weeks * Participation in the Swiss MS Cohort (SMSC) study Exclusion Criteria: * . History of severe (other) neurological, internal or psychiatric disease with SC affection * MRI-related exclusion criteria (questionnaire): 1. Paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the SC) 2. Pacemaker 3. Claustrophobia 4. Pregnancy, lactation 5. Known hypersensitivity to gadolinium-based contrast media
Contact & Investigator
Katrin Parmar, PD Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital Basel, Department of Neurology
Frequently Asked Questions
Who can join the NCT04819737 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis (MS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04819737 currently recruiting?
Yes, NCT04819737 is actively recruiting participants. Contact the research team at katrin.parmar@unibas.ch for enrollment information.
Where is the NCT04819737 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT04819737 clinical trial?
NCT04819737 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Katrin Parmar, PD Dr. med. at University Hospital Basel, Department of Neurology. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.